Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril
about
Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptideCell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysinDual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure.Vasopeptidase inhibitors: will they have a role in clinical practice?The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides.Emerging drugs which target the renin-angiotensin-aldosterone system.Roles of proteolysis in regulation of GPCR function.An update on hybrid drugs in cardiovascular drug research.Metal complexes and metalloproteases: targeting conformational diseases.A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteersPractical implications of current natriuretic peptide research.Effects of a neutral endoprotease enzyme inhibitor, thiorphan, on hemodynamics and renal excretory function in four models of experimental hypertension.
P2860
Q27667064-6BE8A4D9-AFFA-4038-B6C9-DFB1FCF8049DQ28580856-B73B26BC-2A1D-447E-9964-CD8BA4CE37A8Q35214142-3DD24CD7-9708-40FB-BABA-6038E8427181Q35580130-36D505FD-32E2-4837-B610-708D6F01DA90Q35608907-C62C0C1C-19B2-4ADD-A3C1-7EB73314970AQ36835183-5409E41F-426D-4A4C-933E-5926489C8EBAQ37929786-F3D2C33B-4B46-496C-BF72-D1CF48DCC221Q38050189-2698245B-5F1C-4DCE-8058-1A76DA3F3EE7Q38090661-FFC28615-3E56-42FE-833A-1994044B423CQ38215608-4A5C2CE4-98FC-4AD1-9F4C-56031FB74408Q41612183-17279893-CC0E-43C1-8E29-8663EB0D3D6FQ48624965-06C5959A-E32E-4B90-8C48-022348ED8CB5Q51417304-E88646EB-046A-4896-ACAC-563C3669C1B3
P2860
Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mixed inhibitors of angiotensi ...... s of glycopril and alatriopril
@en
Mixed inhibitors of angiotensi ...... of glycopril and alatriopril.
@nl
type
label
Mixed inhibitors of angiotensi ...... s of glycopril and alatriopril
@en
Mixed inhibitors of angiotensi ...... of glycopril and alatriopril.
@nl
prefLabel
Mixed inhibitors of angiotensi ...... s of glycopril and alatriopril
@en
Mixed inhibitors of angiotensi ...... of glycopril and alatriopril.
@nl
P2093
P2860
P356
P1476
Mixed inhibitors of angiotensi ...... s of glycopril and alatriopril
@en
P2093
J C Plaquevent
J C Schwartz
J M Lecomte
P2860
P304
P356
10.1073/PNAS.88.10.4210
P407
P577
1991-05-01T00:00:00Z